Sumit Mistry1, Judith R Harrison2, Daniel J Smith3, Valentina Escott-Price2, Stanley Zammit4. 1. Institute of Psychological Medicine and Clinical Neurosciences, MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, UK. Electronic address: mistrys1@cardiff.ac.uk. 2. Institute of Psychological Medicine and Clinical Neurosciences, MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, UK. 3. Institute of Health and Wellbeing, University of Glasgow, I Lilybank Gardens, UK. 4. Institute of Psychological Medicine and Clinical Neurosciences, MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, UK; Centre for Academic Mental Health, Population Health Sciences, Bristol Medical School, University of Bristol, UK.
Abstract
BACKGROUND: Identifying the phenotypic manifestations of increased genetic liability for depression (MDD) and bipolar disorder (BD) can enhance understanding of their aetiology. The polygenic risk score (PRS) derived using data from genome-wide-association-studies can be used to explore how genetic risk is manifest in different samples. AIMS: In this systematic review, we review studies that examine associations between the MDD and BD polygenic risk scores and phenotypic outcomes. METHODS: Following PRISMA guidelines, we searched EMBASE, Medline and PsycINFO (from August 2009 - 14th March 2016) and references of included studies. Study inclusion was based on predetermined criteria and data were extracted independently and in duplicate. RESULTS: Twenty-five studies were included. Overall, both polygenic risk scores were associated with other psychiatric disorders (not the discovery sample disorder) such as depression, schizophrenia and bipolar disorder, greater symptom severity of depression, membership of a creative profession and greater educational attainment. Both depression and bipolar polygenic risk scores explained small amounts of variance in most phenotypes (< 2%). LIMITATIONS: Many studies did not report standardised effect sizes. This prevented us from conducting a meta-analysis. CONCLUSIONS: Polygenic risk scores for BD and MDD are associated with a range of phenotypes and outcomes. However, they only explain a small amount of the variation in these phenotypes. Larger discovery and adequately powered target samples are required to increase power of the PRS approach. This could elucidate how genetic risk for bipolar disorder and depression is manifest and contribute meaningfully to stratified medicine.
BACKGROUND: Identifying the phenotypic manifestations of increased genetic liability for depression (MDD) and bipolar disorder (BD) can enhance understanding of their aetiology. The polygenic risk score (PRS) derived using data from genome-wide-association-studies can be used to explore how genetic risk is manifest in different samples. AIMS: In this systematic review, we review studies that examine associations between the MDD and BD polygenic risk scores and phenotypic outcomes. METHODS: Following PRISMA guidelines, we searched EMBASE, Medline and PsycINFO (from August 2009 - 14th March 2016) and references of included studies. Study inclusion was based on predetermined criteria and data were extracted independently and in duplicate. RESULTS: Twenty-five studies were included. Overall, both polygenic risk scores were associated with other psychiatric disorders (not the discovery sample disorder) such as depression, schizophrenia and bipolar disorder, greater symptom severity of depression, membership of a creative profession and greater educational attainment. Both depression and bipolar polygenic risk scores explained small amounts of variance in most phenotypes (< 2%). LIMITATIONS: Many studies did not report standardised effect sizes. This prevented us from conducting a meta-analysis. CONCLUSIONS: Polygenic risk scores for BD and MDD are associated with a range of phenotypes and outcomes. However, they only explain a small amount of the variation in these phenotypes. Larger discovery and adequately powered target samples are required to increase power of the PRS approach. This could elucidate how genetic risk for bipolar disorder and depression is manifest and contribute meaningfully to stratified medicine.
Authors: Eric Feczko; Oscar Miranda-Dominguez; Mollie Marr; Alice M Graham; Joel T Nigg; Damien A Fair Journal: Trends Cogn Sci Date: 2019-05-29 Impact factor: 20.229
Authors: Zeynep Yilmaz; Katherine Schaumberg; Matthew Halvorsen; Erica L Goodman; Leigh C Brosof; James J Crowley; Carol A Mathews; Manuel Mattheisen; Gerome Breen; Cynthia M Bulik; Nadia Micali; Stephanie C Zerwas Journal: Psychol Med Date: 2022-03-04 Impact factor: 10.592
Authors: Hale Yapici-Eser; Vivek Appadurai; Candan Yasemin Eren; Dilek Yazici; Chia-Yen Chen; Dost Öngür; Diego A Pizzagalli; Thomas Werge; Mei-Hua Hall Journal: Acta Neuropsychiatr Date: 2020-03-26 Impact factor: 3.403
Authors: Katherine L Musliner; Preben B Mortensen; John J McGrath; Nis P Suppli; David M Hougaard; Jonas Bybjerg-Grauholm; Marie Bækvad-Hansen; Ole Andreassen; Carsten B Pedersen; Marianne G Pedersen; Ole Mors; Merete Nordentoft; Anders D Børglum; Thomas Werge; Esben Agerbo Journal: JAMA Psychiatry Date: 2019-05-01 Impact factor: 21.596
Authors: Ashley L Comes; Fanny Senner; Monika Budde; Kristina Adorjan; Heike Anderson-Schmidt; Till F M Andlauer; Katrin Gade; Maria Hake; Urs Heilbronner; Janos L Kalman; Daniela Reich-Erkelenz; Farah Klöhn-Saghatolislam; Sabrina K Schaupp; Eva C Schulte; Georg Juckel; Udo Dannlowski; Max Schmauß; Jörg Zimmermann; Jens Reimer; Eva Reininghaus; Ion-George Anghelescu; Volker Arolt; Bernhard T Baune; Carsten Konrad; Andreas Thiel; Andreas J Fallgatter; Vanessa Nieratschker; Christian Figge; Martin von Hagen; Manfred Koller; Thomas Becker; Moritz E Wigand; Markus Jäger; Detlef E Dietrich; Sebastian Stierl; Harald Scherk; Carsten Spitzer; Here Folkerts; Stephanie H Witt; Franziska Degenhardt; Andreas J Forstner; Marcella Rietschel; Markus M Nöthen; Jens Wiltfang; Peter Falkai; Thomas G Schulze; Sergi Papiol Journal: Transl Psychiatry Date: 2019-08-28 Impact factor: 6.222
Authors: Marco Solmi; Joaquim Radua; Brendon Stubbs; Valdo Ricca; Davide Moretti; Daniele Busatta; Andre F Carvalho; Elena Dragioti; Angela Favaro; Alessio Maria Monteleone; Jae Il Shin; Paolo Fusar-Poli; Giovanni Castellini Journal: Braz J Psychiatry Date: 2020-09-28 Impact factor: 2.697